Developing a successful generic product for an ANDA submission is far more than matching the composition of the Reference Listed Drug (RLD). Many project failures, delays, and regulatory observations arise from avoidable mistakes during development.
Some of the most common pitfalls include:
- Inadequate understanding of the RLD and its critical quality attributes (CQAs)
- Insufficient preformulation studies and incomplete API characterization
- Poor formulation development strategy and lack of a Quality by Design (QbD) approach
- Inadequate dissolution method development and non-discriminatory methods
- Inappropriate excipient selection and failure to assess functionality-related characteristics (FRCs)
- Insufficient process understanding and identification of critical process parameters (CPPs)
- Weak risk assessment and ineffective control strategies
- Deficiencies in bioequivalence (BE) planning and execution
- Inadequate stability studies and packaging evaluation
- Weak analytical method development and validation practices
- Inadequate nitrosamine risk assessment and control strategies
- Poor documentation and investigation practices
- Weak technology transfer from R&D to manufacturing
- Underestimating regulatory expectations and product-specific guidance (PSG)
The consequences?
Bioequivalence failures, batch failures, stability issues, regulatory observations, repeated studies, launch delays, and multiple review cycles.
Successful ANDA development requires a science- and risk-based approach:
Comprehensive RLD characterization → Scientific formulation development → Robust process understanding → Effective risk management → Strong analytical and stability programs → Well-planned BE strategy → Thorough documentation and regulatory compliance.
Most ANDA delays occur not because of a lack of technical capability, but because of inadequate product understanding, poor development planning, and insufficient documentation throughout the product lifecycle.
What additional challenges have you encountered during generic product development and ANDA submissions?
Read also: Practical Approaches to Pharmaceutical Formulation Development
Resource Person: Vijay Agrawal
